Use of carbamazepine in psychiatric disorders

L. J. Birkhimer, J. L. Curtis, Michael Wong Jann

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Use of carbamazepine for the treatment of psychiatric disorders is reviewed. Carbamazepine's mechanism of action may be related to inhibition of kindling (repeated subtherapeutic electrical stimulation) in the temporal lobe and limbic system. In most published studies, carbamazepine was useful in affective disorders, especially in patients with bipolar manic disorders. In controlled, double-blind studies in patients with primary affective or schizoaffective disorders, carbamazepine significantly decreased manic symptoms and showed some antidepressant effect. Synergistic effects have been observed when carbamazepine is used with lithium. Carbamazepine has been reported to decrease symptoms in patients with aggression, dyscontrol syndromes, schizophrenia, and alcohol withdrawal syndrome, but few of these studies have been controlled, comparative trials; carbamazepine may be useful in patients with these disorders who do not respond to conventional therapies. Beneficial effects of carbamazepine in psychiatric disorders are usually observed with doses of 400-1600 mg/day and serum concentrations of 8-12 μg/mL. Carbamazepine is useful alone or in combination with other agents for bipolar affective disorders, especially in patients who are intolerant of or unresponsive to lithium. Serum carbamazepine concentration, hematological profile, and serum electrolytes should be monitored carefully to minimize the risk toxicity.

Original languageEnglish
Pages (from-to)425-434
Number of pages10
JournalClinical Pharmacy
Volume4
Issue number4
StatePublished - 1 Jan 1985

Fingerprint

Carbamazepine
Psychiatry
Mood Disorders
Bipolar Disorder
Lithium
Serum
Limbic System
Temporal Lobe
Aggression
Double-Blind Method
Psychotic Disorders
Electrolytes
Antidepressive Agents
Electric Stimulation
Schizophrenia
Alcohols

Cite this

Birkhimer, L. J., Curtis, J. L., & Jann, M. W. (1985). Use of carbamazepine in psychiatric disorders. Clinical Pharmacy, 4(4), 425-434.
Birkhimer, L. J. ; Curtis, J. L. ; Jann, Michael Wong. / Use of carbamazepine in psychiatric disorders. In: Clinical Pharmacy. 1985 ; Vol. 4, No. 4. pp. 425-434.
@article{77a0f0315a834240b7f862354ad0fc5d,
title = "Use of carbamazepine in psychiatric disorders",
abstract = "Use of carbamazepine for the treatment of psychiatric disorders is reviewed. Carbamazepine's mechanism of action may be related to inhibition of kindling (repeated subtherapeutic electrical stimulation) in the temporal lobe and limbic system. In most published studies, carbamazepine was useful in affective disorders, especially in patients with bipolar manic disorders. In controlled, double-blind studies in patients with primary affective or schizoaffective disorders, carbamazepine significantly decreased manic symptoms and showed some antidepressant effect. Synergistic effects have been observed when carbamazepine is used with lithium. Carbamazepine has been reported to decrease symptoms in patients with aggression, dyscontrol syndromes, schizophrenia, and alcohol withdrawal syndrome, but few of these studies have been controlled, comparative trials; carbamazepine may be useful in patients with these disorders who do not respond to conventional therapies. Beneficial effects of carbamazepine in psychiatric disorders are usually observed with doses of 400-1600 mg/day and serum concentrations of 8-12 μg/mL. Carbamazepine is useful alone or in combination with other agents for bipolar affective disorders, especially in patients who are intolerant of or unresponsive to lithium. Serum carbamazepine concentration, hematological profile, and serum electrolytes should be monitored carefully to minimize the risk toxicity.",
author = "Birkhimer, {L. J.} and Curtis, {J. L.} and Jann, {Michael Wong}",
year = "1985",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "425--434",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "4",

}

Birkhimer, LJ, Curtis, JL & Jann, MW 1985, 'Use of carbamazepine in psychiatric disorders', Clinical Pharmacy, vol. 4, no. 4, pp. 425-434.

Use of carbamazepine in psychiatric disorders. / Birkhimer, L. J.; Curtis, J. L.; Jann, Michael Wong.

In: Clinical Pharmacy, Vol. 4, No. 4, 01.01.1985, p. 425-434.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of carbamazepine in psychiatric disorders

AU - Birkhimer, L. J.

AU - Curtis, J. L.

AU - Jann, Michael Wong

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Use of carbamazepine for the treatment of psychiatric disorders is reviewed. Carbamazepine's mechanism of action may be related to inhibition of kindling (repeated subtherapeutic electrical stimulation) in the temporal lobe and limbic system. In most published studies, carbamazepine was useful in affective disorders, especially in patients with bipolar manic disorders. In controlled, double-blind studies in patients with primary affective or schizoaffective disorders, carbamazepine significantly decreased manic symptoms and showed some antidepressant effect. Synergistic effects have been observed when carbamazepine is used with lithium. Carbamazepine has been reported to decrease symptoms in patients with aggression, dyscontrol syndromes, schizophrenia, and alcohol withdrawal syndrome, but few of these studies have been controlled, comparative trials; carbamazepine may be useful in patients with these disorders who do not respond to conventional therapies. Beneficial effects of carbamazepine in psychiatric disorders are usually observed with doses of 400-1600 mg/day and serum concentrations of 8-12 μg/mL. Carbamazepine is useful alone or in combination with other agents for bipolar affective disorders, especially in patients who are intolerant of or unresponsive to lithium. Serum carbamazepine concentration, hematological profile, and serum electrolytes should be monitored carefully to minimize the risk toxicity.

AB - Use of carbamazepine for the treatment of psychiatric disorders is reviewed. Carbamazepine's mechanism of action may be related to inhibition of kindling (repeated subtherapeutic electrical stimulation) in the temporal lobe and limbic system. In most published studies, carbamazepine was useful in affective disorders, especially in patients with bipolar manic disorders. In controlled, double-blind studies in patients with primary affective or schizoaffective disorders, carbamazepine significantly decreased manic symptoms and showed some antidepressant effect. Synergistic effects have been observed when carbamazepine is used with lithium. Carbamazepine has been reported to decrease symptoms in patients with aggression, dyscontrol syndromes, schizophrenia, and alcohol withdrawal syndrome, but few of these studies have been controlled, comparative trials; carbamazepine may be useful in patients with these disorders who do not respond to conventional therapies. Beneficial effects of carbamazepine in psychiatric disorders are usually observed with doses of 400-1600 mg/day and serum concentrations of 8-12 μg/mL. Carbamazepine is useful alone or in combination with other agents for bipolar affective disorders, especially in patients who are intolerant of or unresponsive to lithium. Serum carbamazepine concentration, hematological profile, and serum electrolytes should be monitored carefully to minimize the risk toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0021927926&partnerID=8YFLogxK

M3 - Article

C2 - 2864160

AN - SCOPUS:0021927926

VL - 4

SP - 425

EP - 434

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 4

ER -

Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clinical Pharmacy. 1985 Jan 1;4(4):425-434.